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Abstract 
Background: The urinary proteomic classifier CKD273 has shown promise for prediction of progressive diabetic 
nephropathy (DN). Whether it is also a determinant of mortality and cardiovascular disease in patients with microalbu‑
minuria (MA) is unknown.
Methods: Urine samples were obtained from 155 patients with type 2 diabetes and confirmed microalbuminuria. 
Proteomic analysis was undertaken using capillary electrophoresis coupled to mass spectrometry to determine the 
CKD273 classifier score. A previously defined CKD273 threshold of 0.343 for identification of DN was used to catego‑
rise the cohort in Kaplan–Meier and Cox regression models with all‑cause mortality as the primary endpoint. Out‑
comes were traced through national health registers after 6 years.
Results: CKD273 correlated with urine albumin excretion rate (UAER) (r = 0.481, p = <0.001), age (r = 0.238, p = 0.003), 
coronary artery calcium (CAC) score (r = 0.236, p = 0.003), N‑terminal pro‑brain natriuretic peptide (NT‑proBNP) 
(r = 0.190, p = 0.018) and estimated glomerular filtration rate (eGFR) (r = 0.265, p = 0.001). On multivariate analysis only 
UAER (β = 0.402, p < 0.001) and eGFR (β = − 0.184, p = 0.039) were statistically significant determinants of CKD273. 
Twenty participants died during follow‑up. CKD273 was a determinant of mortality (log rank [Mantel‑Cox] p = 0.004), 
and retained significance (p = 0.048) after adjustment for age, sex, blood pressure, NT‑proBNP and CAC score in a Cox 
regression model.
Conclusion: A multidimensional biomarker can provide information on outcomes associated with its primary diag‑
nostic purpose. Here we demonstrate that the urinary proteomic classifier CKD273 is associated with mortality in indi‑
viduals with type 2 diabetes and MA even when adjusted for other established cardiovascular and renal biomarkers.
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Background
It is estimated that around 35% of individuals affected by 
type 2 diabetes will develop DN [1] which is characterised 
by elevated UAER and declining renal function. Patients 
with DN are at particularly high risk of mortality, driven 
primarily by cardiovascular disease [2]. Microalbumi-
nuria [MA, defined as UAER > 30  mg/24  h or urinary 
albumin creatinine ratio (UACR) 30  mg/g creatinine] is 
the earliest clinical hallmark of DN, and both UAER and 
eGFR have been shown to independently predict car-
diovascular mortality as well as renal events in patients 
with type 2 diabetes [3]. Despite this, the utility of MA 
as a biomarker is limited by a number of factors includ-
ing its variability and lack of sensitivity at low levels [4]. 
Furthermore, progression rates amongst individuals with 
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MA are lower than previously thought [5] and we now 
know that MA will regress in around one-third of indi-
viduals [6]. As a result, alternative biomarkers to iden-
tify those at highest risk of progressive renal disease and 
associated cardiovascular diseases are needed in order to 
target intensified risk factor management and preventa-
tive therapies towards this subpopulation.
Proteomics involves the large-scale separation and 
quantification of proteins and polypeptides within a bio-
logical sample and is a promising technique for identi-
fication of complex conditions such as DN, as features 
derived from multiple underlying disease pathways can 
be measured simultaneously. Urine is an attractive bio-
fluid for proteomic studies in the context of DN as it is 
not only produced by the kidneys but also contains pep-
tides that are stable and can be subjected to mass spec-
trometry without further digestion. Urinary proteomic 
studies have demonstrated significant associations of 
multiple urinary peptides with diabetes [7] and DN [8]. 
The CKD273 classifier is a panel of 273 peptides which 
are differentially regulated in the urine of patients with 
chronic kidney disease (CKD) compared to healthy con-
trols [9]. CKD273 has shown promise as a tool for early 
detection of DN risk [10–12] and this is currently being 
assessed in a multicentre prospective clinical trial [13]. 
However, the utility of CKD273 as a predictor of death 
associated with DN has not yet been investigated.
We have previously shown in a cohort of 200 individu-
als with type 2 diabetes and MA who were free from 
coronary artery disease at baseline that NT-proBNP and 
CAC score are determinants of fatal and non-fatal car-
diovascular events as well as all-cause mortality over a 
median follow-up period of 6.1 years [14]. We have now 
analysed baseline samples from this cohort to study the 
association of CKD273 with mortality.
Methods
Participant recruitment
Recruitment, study procedures and sample size consid-
erations have previously been published elsewhere [14, 
15]. In brief, a cohort of 200 patients with type 2 diabe-
tes receiving intensive multifactorial intervention as per 
the Steno 2 protocol [16] were identified at the Steno 
Diabetes Center over a 12  month period between Feb-
ruary 2007 and February 2008. Individuals with symp-
toms suggestive of coronary artery disease were excluded 
from the study, as were those with Q-waves evident on 
12-lead electrocardiography; contraindications to CT 
angiography including abnormal plasma creatinine; and 
malignancy. All participants gave informed consent; the 
study was approved by the local ethics committee and is 
in accordance with the Declaration of Helsinki.
Study procedures
Cardiac computed tomography was conducted using a 
16 multidetector-row CT scanner with 3 mm slice thick-
ness during a single breath hold (Philips Precedence MX 
8000IDT 16-slice; Philips Medical Systems, Best, The 
Netherlands). A separate workstation with dedicated 
software (Heartbeat-CS, EBW; Philips Medical Systems) 
was used to quantify total CAC score for each participant 
based on intimal and medial calcification in the left main, 
left anterior descending, circumflex and right coronary 
arteries. NT-proBNP was measured at baseline in all par-
ticipants by immunoassay as previously described [17]. 
UAER was measured by immunoassay in three consecu-
tive 24-h collections and geometric mean was calculated 
[18]. The Chronic Kidney Disease Epidemiology Collabo-
ration (CKD-EPI) equation was used to calculate eGFR 
from plasma creatinine [19].
Urinary proteomics
Sample selection and preparation
Urine samples from baseline visits were used for the pre-
sent study with selection based on sample availability. 
Specimens were available from 188 participants however 
33 of these failed quality control assessment, leaving 155 
datasets for analysis. Overall, clinical characteristics of 
these patients were not different from the whole study 
group except for higher levels of UAER in samples that 
failed quality control for proteomics (data not shown). 
Specimens were stored at − 80  °C from collection until 
preparation. A 0.7  mL aliquot was thawed, diluted with 
0.7  mL urea (2  mol/L) and  NH4OH (10  mmol/L) con-
taining 0.02% sodium dodecyl sulphate prior to filtration 
at 3000  g using a Centrisart ultracentrifugation device 
with molecular mass cut-off of 20  kDa (Sartorius, Göt-
tigen, Germany) until 1.1  mL of filtrate was obtained. 
Samples were then desalinised using PD-10 columns (GE 
Healthcare, Stockholm, Sweden) equilibrated with 0.01% 
 NH4OH in HPLC-grade water. Samples were lipophilised 
and resuspended in HPLC-grade water to a final protein 
concentration of 0.8 µg/µL.
Sample and data processing
Study team members were blinded to clinical character-
istics during sample analysis. Urinary proteomic analy-
sis was performed by capillary electrophoresis coupled 
to mass spectrometry (CE–MS) using a P/ACE MDQ 
capillary electrophoresis system (Beckman Coulter, 
USA) coupled to micro-time of flight mass spectrom-
eter (Bruker Daltonic, Germany) as previously described 
[9]. The repeatability and stability of this technique has 
previously been evaluated [20]. Mass spectral ion peaks 
representing identical molecules at different charge states 
were deconvoluted into single masses using bespoke 
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Mosaiques Visu software [21]. Normalisation of analyti-
cal and urine dilution variances was performed against 29 
“housekeeper” peptides which are consistently present in 
urine with minimal relative standard deviation (SD) [22]. 
All detected peptides were deposited, matched and anno-
tated in a Microsoft SQL database. Data pertaining to the 
273 urinary peptides represented by the CKD273 clas-
sifier were then translated into a single numerical score, 
or classification factor, using support vector machine 
modelling. Previous studies have confirmed that a score 
of > 0.343 is the best established threshold for identifica-
tion of patients at highest risk of progression to overt DN 
[9, 10, 12]. Additional analyses were performed with the 
CAD238 urinary proteomic classifier, generated using the 
same methodology, for detection of coronary artery dis-
ease [23].
Endpoints
The primary endpoint was defined as death from any 
cause. Secondary endpoints were cardiovascular events 
(4-point MACE including non-fatal myocardial infarc-
tion, stroke, hospitalisation for heart failure and car-
diovascular death); decline in eGFR of at least 30% and 
transition to macroalbuminuria at any time point during 
the follow up period. All study participants were traced 
through Danish National Health registries from 1st Janu-
ary 2014.
Statistical analysis
SPSS statistics 22 (IBM Analytics, New York, USA) was 
used for statistical analysis. Normally distributed data are 
expressed as mean ± SD while nonparametric data are 
expressed as median (range). UAER data are expressed 
as geometric mean and interquartile range. Correlations 
were determined by Pearson’s method and high and low-
risk groups were compared by 2-sample t test, both using 
log transformed data where appropriate. Kaplan–Meier 
analysis was used for survival studies where p values were 
derived from Log Rank (Mantel Cox) test. Cox regression 
analysis was performed to generate fully adjusted sur-
vival data. Receiver Operator Curve (ROC) analysis we 
performed on significant predictors of mortality where 
predicted probabilities from logistic regression analysis 
of individual variables were used as test variable where 
indicated. For comparison of areas under the the ROC 
curves (AUCs) the DeLong method was used in MedCalc 
software version 17.9.7 (Ostend, Belgium) Level of signif-
icance was set to 0.05.
Results
Cross‑sectional analysis
Baseline characteristics of the 155 study participants in 
whom CKD273 classifier scores were available are shown 
in Table 1. With the exception of body mass index (BMI) 
traditional risk factors were well-controlled in the con-
text of a multifactorial intervention strategy. Renal func-
tion was preserved (mean eGFR > 60  mL/min/1.73  m2) 
and geometric mean of UAER was within the microalbu-
minuric range.
Examination of the dataset according to CKD273 
classifier score revealed that 69 participants (45%) had 
CKD273 classifier score > 0.343, while 86 (55%) fell below 
this threshold. Comparison of clinical and biochemical 
parameters according to CKD classifier risk threshold is 
shown in Table  2. While age, BMI, blood pressure, gly-
cated haemoglobin (HbA1c) were similar between high 
and low risk patients, those with classifier score above 
0.343 had lower eGFR and higher UAER. In addition, 
these participants also had significantly higher CAC 
score.
We then analysed CKD273 classifier score as con-
tinuous variable in the whole study group and found an 
inverse correlation with eGFR (r = − 0.265, p = 0.001) and 
a direct correlation with UAER (r = 0.481, p = <0.001). 
There was no significant difference in CKD273 between 
male and female participants, and no correlation with 
other clinical parameters with the exception of age 
(Additional file  1: Figure S1). In a multivariate regres-
sion model including age, sex, eGFR and UAER; only 
Table 1 Baseline characteristics
BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, 
HbA1c glycated haemoglobin, HDL high density lipoprotein, LDL low density 
lipoprotein, eGFR estimated glomerular filtration rate, UAER urine albumin 
excretion rate, NT-proBNP N-terminal pro-brain natriuretic peptide, CAC coronary 
artery calcium. Data are mean ± SD or median (range). UAER expressed as 
geometric mean and interquartile range. eGFR determined by CKD-EPI formula
Parameter Value
Age (years) 61 (29–71)
Diabetes duration (years) 13 (1–36)
Sex (m/f ) 118/37
Smokers (year/n) 42/113
BMI (kg/m2) 31.6 (21.6–55.6)
SBP (mmHg) 129 ± 16
DBP (mmHg) 74 ± 11
HbA1c [%] (mmol/mol) [7.6] 58.5 (39–123)
Cholesterol (mmol/L) 3.8 (2–6.7)
HDL (mmol/L) 1.1 (0.4–3.1)
LDL (mmol/L) 1.7 (0.4–4.4)
Creatinine (µmol/L) 77 ± 17.6
eGFR (mL/min/1.73 m2) 88 ± 17
UAER (mg/24 h) 85 [34;194]
CKD273 0.268 (− 1.08 to 1.23)
CAD238 − 0.513 ± 0.256
NT‑proBNP (ng/L) 45 (5–576)
CAC score 501 ± 771
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eGFR and UAER remained as significant determinants 
of CKD273 classifier score, together explaining 30% of its 
variability. Pearson correlation analysis did reveal a linear 
association between CKD273 score and the cardiovascu-
lar biomarkers NT-proBNP and CAC score (Additional 
file 1: Figure S2).
Longitudinal analysis
During the follow up period 19 participants (12%) tran-
sitioned from micro- to macro-albuminuria, while 29 
(18%) experienced a 30% decline in eGFR. Eight par-
ticipants (5%) experienced both endpoints. Baseline 
CKD273 score was higher in those who experienced a 
renal endpoint compared to those who did not, but only 
reached statistical significance in those who transitioned 
in albuminuria status (Table  3). Kaplan–Meier analy-
sis showed that CKD273 score above the risk threshold 
for DN was not predictive of a 30% eGFR decline over a 
6-year follow up period in this cohort (Additional file 1: 
Figure S3), nor was classifier score correlated with abso-
lute change in UAER (Additional file 1: Figure S4).
Cardiovascular events occurred in 31 (20%) par-
ticipants. Baseline CKD273 classifier score was not 
significantly different in those who experienced a cardi-
ovascular event, nor was it found to be associated with 
cardiovascular events on Kaplan–Meier analysis. Survival 
analysis was also performed using the CAD238 classi-
fier, developed for prediction of cardiovascular events. 
Here the association with cardiovascular events during 
follow-up approached statistical significance and logistic 
Table 2 Clinical characteristics according to CKD273 risk threshold
BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, HbA1c glycated haemoglobin, HDL high density lipoprotein, LDL low density 
lipoprotein, eGFR estimated glomerular filtration rate, UAER urine albumin excretion rate, NT-proBNP N-terminal pro-brain natriuretic peptide, CAC coronary artery 
calcium. Data are mean ± SD or median (range). UAER expressed as geometric mean and interquartile range. eGFR determined by CKD-EPI formula. p < 0.05 and * 
denote statistical significance. Comparisons between groups are by 2-sample t test or appropriately transformed data where necessary. Numerical CKD273 cut-off for 
diagnosis of DN is 0.343
Parameter CKD273 > 0.343 (n = 69) CKD273 < 0.343 (n = 86) p value
Age (years) 62 (32–71) 61 (29–71) 0.173
Diabetes duration (years) 13 (1–35) 12.5 (1–36) 0.455
Gender (m/f ) 59/10 59/27 *0.014
Smokers (year/n) 24/45 18/68 0.054
BMI (kg/m2) 31 (23–56) 32 (22–48) 0.324
SBP (mmHg) 130 ± 17 129 ± 16 0.725
DBP (mmHg) 74 ± 11 75 ± 12 0.574
HbA1c [%] (mmol/mol) [7.5] 58 (42–110) [7.6] 60 (39–123) 0.267
Cholesterol (mmol/L) 3.9 (2.3–6.7) 3.8 (2–6.6) 0.893
HDL (mmol/L) 1.1 (0.4–2.2) 1.1 (0.7–3.1) 0.066
LDL (mmol/L) 1.8 (0.5–4.4) 1.7 (0.4–4.2) 0.342
Creat (µmol/L) 80 ± 18 75 ± 17 *0.049
eGFR (mL/min/1.73 m2) 86 ± 18 90 ± 15 0.143
UAER (mg/24 h) 148 [70;385] 55 [29;99] *< 0.001
CKD273 0.546 (0.369–1.231) 0.041 (− 1.078 to 0.347) *< 0.001
CAD238 − 0.463 ± 0.202 − 0.586 ± 0.281 *0.002
NT‑proBNP (ng/L) 52 (5–550) 42 (5–576) 0.615
CAC score 676 ± 961 363 ± 547 0.018
Table 3 Comparison of classifier scores in patients who reached an endpoint compared to those who did not
We defined the following endpoints for analysis: (1) All-cause mortality. (2) CV events. (3) 30% decline in eGFR. (4) Transition from micro to macroalbuminuria. With 
regard to the latter, there were 19 patients who progressed and 73 who remained microalbuminuric or regressed; we did not analyse data on people who were 
macroalbuminuric at baseline. Data are mean ± SD, p value of < 0.05 deemed statistically significant. Comparisons are by 2 sample t test. p < 0.05 and * denote 
statistical significance
Endpoint Yes No p value
30% decline eGFR (29 events) 0.239 ± 0.414 0.228 ± 0.390 0.886
Transition micro to macroalbuminuria (19 events) 0.354 ± 0.238 0.145 ± 0.406 *0.036
Cardiovascular event (31 events) 0.331 ± 0.389 0.216 ± 0.405 0.156
Mortality (20 events) 0.438 ± 0.355 0.208 ± 0.403 *0.017
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regression analysis confirmed that CAD238 was associ-
ated with imaging-proven coronary artery disease whilst 
CKD273 was not (Additional file 1: Figure S5, Table S1).
Twenty (13%) participants died during follow up. Ten 
(50%) of these events were cardiovascular deaths. Base-
line CKD273 classifier score was significantly higher in 
those who died compare to survivors (Table 3). Survivors 
were younger and less likely to smoke (Additional file 1: 
Table S2). Kaplan–Meier analysis revealed that CKD273 
classifier score above 0.343 was associated with mortality 
over 6 years follow up (Fig. 1). Active smoking was also a 
statistically significant determinant of death in Kaplan–
Meier analysis (Log Rank (Mantel-Cox) p = 0.014). In 
order to adjust for continuous variables and other poten-
tial determinants of mortality we then included CKD273 
(above and below the 0.343 threshold) in a more com-
prehensive model adjusted for age, sex, systolic blood 
pressure, smoking status, eGFR, UAER, CAC score and 
NT-proBNP. Only NT-proBNP (p = 0.03), CAC score 
(p = 0.006) and CKD273 (p = 0.048) remained significant 
determinants of mortality (supplementary Table  3). On 
ROC analysis the AUC of the combined predictive value 
of NT-proBNP and CAC score was 0.797. If this was 
combined with CKD273 the AUC was 0.818 (p = 0.376 
for comparison of the AUCs) whereas CKD273 on its 
own resulted in an AUC of 0.662 (Additional file 1: Figure 
S6).
Discussion
Patients with even the early stages of DN are at increased 
risk of death both directly and indirectly as a conse-
quence of the associated cardiovascular disease burden 
[24, 25]. The presence of MA is currently the best clini-
cally applied marker of DN risk, but it is highly variable 
and does not necessarily herald the onset of irreversible 
decline in kidney function [5, 6]. Alternative biomarkers 
to identify those at highest risk of comorbidity associated 
with diabetes would allow targeting of preventative strat-
egies towards these individuals. Here we have shown that 
the CKD273 urinary proteomic classifier for detection 
of DN is associated with later mortality in patients with 
type 2 diabetes and MA.
Both UAER and eGFR are independent and addi-
tive predictors of cardiovascular events and mortality in 
patients with diabetes as well as within the general popu-
lation [26]. In addition to these risk markers the partici-
pants in this study had baseline measurements of CAC 
score and NT-proBNP which have already been shown 
to be associated with cardiovascular events and mor-
tality in this population [14]. CAC score, as a reflection 
of underlying atherosclerotic disease burden, has been 
shown in several studies to reliably inform assessment of 
all-cause mortality and cardiovascular event risk in indi-
viduals with diabetes [27–29]. NT-proBNP is secreted 
in response to cardiomyocyte stretch and has also been 
shown to powerfully predict mortality in cohorts of indi-
viduals with diabetes [17, 30]. The availability of these 
parameters offered us the opportunity to determine the 
performance of the CKD273 classifier in comparison to 
already established clinical tools with proven value in 
predicting mortality. Our data suggest that the CKD273 
is associated with mortality in this cohort of patients with 
type 2 diabetes and MA independently of these estab-
lished risk markers.
The CKD273 urinary proteomic classifier has shown 
some promise as a tool for detection of DN risk. Classi-
fier score has been demonstrated to be associated with 
later progression to MA in normoalbuminuric patients 
[10, 12]; to identify individuals who later transition to 
macroalbuminuria [11]; and to change towards a “health-
ier” value in patients treated with renin angiotensin sys-
tem blocking agents [31]. The utility of CKD273 in the 
early detection of DN followed by specific treatment is 
currently being formally tested prospectively in a mul-
ticentre trial [12]. Studies in populations with CKD of 
mixed aetiology have shown that CKD273 score is pre-
dictive of later requirement for dialysis [32] and is use-
ful for identification of those who display rapid decline in 
eGFR during follow-up [21]. It seems surprising then that 
we have not been able to show the same potential in this 
cohort. This may simply be an issue of statistical power 
as the number of renal endpoints was small and follow 
up relatively short, however it should also be considered 
in the context of recent general population data which 
suggested that the CKD273 classifier is most useful as a 
CKD273 ≤0.343
CKD243 >0.343
Log Rank (Mantel Cox) p=0.004
Fig. 1 Kaplan–Meier plot CKD273 and mortality. Kaplan Meier 
analysis revealed that CKD273 classifier score above the predefined 
threshold for diagnosis of DN (0.343) was predictive of mortality over 
6 years follow up (Log Rank [Mantel Cox] p = 0.004). Black line rep‑
resents classifier score below 0.343; dotted line represents classifier 
score above 0.343
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predictor of progressive kidney disease in patients with 
preserved renal function (eGFR > 70  mL/min/1.73  m2) 
and is of less value in cohorts where renal disease is 
already established [33, 34]. The mean eGFR in our 
cohort was 88  mL/min/1.73  m2 but these patients have 
MA, which reflects the 3rd step in the traditional 5-stage 
natural history of DN [35]. Given that the classifier shows 
most promise as an early, in fact “pre-clinical”, predictor 
of progressive DN we would not necessarily expect it to 
perform as well in a cohort of patients where the disease 
is already established.
The main finding of this study is that the CKD273 
classifier was associated with all-cause mortality in our 
cohort and so could provide additional information on 
other comorbidities associated with CKD. CKD273 is a 
composite of 273 differentially regulated urinary pep-
tides. These are primarily fragments of collagens type 1 
and type 3 but peptides corresponding to source proteins 
such as albumin, uromodulin and α-1 antitrypsin are also 
captured by the classifier, which therefore simultaneously 
reflects multiple altered disease pathways [9]. In view of 
the fact that altered collagen turnover is key to progres-
sion of both kidney disease and cardiovascular disease 
and collagens type 1 and 3 are more predominant within 
the vasculature than the glomerular basement membrane 
it seems intuitive that CKD273 may not only be a marker 
of renal but also a non-specific marker of cardiovascular 
disease akin to MA. Our data do not demonstrate pre-
diction of cardiovascular events by CKD273 in patients 
with type 2 diabetes and MA, however the association of 
CKD273 with DN and altered collagen turnover do sug-
gest a link to microvascular disease and hence mortal-
ity. In recent years specific proteomic panels have been 
developed for identification of atherosclerotic disease 
in animal models and for prediction of CAD in human 
subjects [36, 37]. The CAD238 classifier for prediction of 
coronary artery disease showed a stronger signal in this 
analysis and these data support the use of multimarker 
proteomic panels for diagnosis of specific conditions.
This is the first study to test the predictive power of the 
CKD273 classifier for all-cause mortality in a cohort of 
patients with MA and preserved eGFR in comparison to 
other established risk markers such as NT-proBNP and 
CAC score. Strengths of this study include a well-pheno-
typed cohort with longitudinal follow-up data available. 
In addition we were able to formally test the predictive 
power of the CKD273 classifier alongside a number of 
established clinical risk markers such as eGFR, UAER, 
CAC score and NT-proBNP, which is a prerequisite 
when determining the utility of novel biomarkers. There 
are however several limitations to consider. Firstly the 
original sample size is relatively small and event rate over 
the 6-year follow up period is low, both of which may 
have affected the robustness of our analysis. In addition, 
although analysed as a secondary outcome, our choice 
of 30% eGFR decline as a renal endpoint is less robust 
than doubling of serum creatinine or 40% eGFR decline. 
This decision was made based on the fact that the num-
ber of renal endpoints was low and the primary aim of 
this analysis was to assess prediction of mortality rather 
than renal events. Although our data suggest association 
between CKD273 and mortality independent of a selec-
tion of established traditional and novel risk biomark-
ers it should be borne in mind that multiple processes, 
including for example inflammation and oxidative stress, 
underpin the development of cardiovascular and renal 
disease in diabetes [38] [39, 40]. Whilst multimarker 
omics strategies offer the opportunity to capture changes 
in multiple disease processes simultaneously numerous 
alternative biomarkers remain under evaluation and for 
the time being few have made the transition into routine 
clinical practice.
Conclusions
In conclusion, the CKD273 urinary proteomic classifier is 
associated with mortality in this cohort of patients with 
type 2 diabetes and MA independent of selected estab-
lished clinical risk markers. These findings, although 
promising, require further confirmation on a larger scale 
in independent cohorts.
Additional file
Additional file 1: Figure S1. Univariate determinants of CKD273. eGFR, 
estimated glomerular filtration rate; UAER, urine albumin excretion rate. 
Analysis by Pearson correlation on appropriately transformed data where 
necessary. CKD273 classifier score correlated with age (panel A; r=0.238, 
p=0.003); eGFR (panel B; r=‑0.265, p=0.001) and UAER (panel C; r=0.481, 
p=<0.001). There was no significant difference in classifier score between 
men and women, and no correlation with other traditional clinical 
parameters. Figure S2. Correlations between CKD273 and cardiovascular 
biomarkers. CAC, coronary artery calcium score; BNP, brain natriuretic 
peptide. CKD273 correlated with CAC score (left panel; r=0.236, p=0.003) 
and NT‑proBNP (right panel; r=0.190, p=0.018). Correlations by Pearson’s 
method on appropriately transformed data where necessary. P < 0.05 
deemed statistically significant. Figure S3. Kaplan Meier plot of CKD273 
and primary renal endpoint (30% decline in eGFR). eGFR, estimated glo‑
merular filtration rate. Blue line represents classifier score < 0.343; green 
line represents classifier score > 0.343. Kaplan Meier analysis revealed that 
CKD273 classifier score above the predefined threshold for diagnosis of 
DN (0.343) did not predict 30% decline in eGFR (Log Rank [Mantel Cox] 
p=0.598). Figure S4. Correlation plot showing relationship between 
CKD273 and change in UAER over follow up. Correlation is by Pearson’s 
method on log10 transformed data. P < 0.05 deemed statistically signifi‑
cant. The correlation between CKD273 classifier score at baseline and 
change in UAER did not reach statistical significance (r=0.249, p=0.072). 
Figure S5. Kaplan Meier plot of CAD238 and cardiovascular events over 
follow up. Kaplan Meier analysis revealed that CAD238 classifier score in 
the highest quartile showed a trend towards prediction of cardiovascular 
events which did not reach statistical significance (Log Rank [Mantel Cox] 
p=0.055). Table S1. Logistic regression model for imaging‑proven CAD. 
Here we use NT‑proBNP and coronary artery calcification scores above 
thresholds determined in a previous publication for identification of 
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